Neurosciencies and Pain Research

Allentown, Pennsylvania 18103-6296

0 studies enrolling now · 1 studies all time

What they study most

Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed